State Pension payments are rising next month - these are the new weekly rates
dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.
State Pension payments will rise in April - these are the new weekly rates
dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.
I WAS pleased to read Tim Rideout and John Robson’s, “We need to bust the myth that a deficit is a bad thing” (Letters, February 17). It is not. A deficit is the norm. Included in Tim and John’s article were four issues that have to be continually brought to the fore to combat the same old potatoes being brought out ad nauseam by Unionist pundits and politicians – currency, national debt, deficit and pensions. It is important that an independent Scotland break free from the financial shackles of Westminster Treasury decisions and it can only do so by establishing its own currency as soon as possible. By all means align it with Sterling, the euro and US dollar for the first two or three years but, for those who want to rejoin the EU, we have to have our own free floating currency for a few years before we can even contemplate re-entry. What we call our new currency is irrelevant.
Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020
News provided by
Share this article
Share this article
TOKYO and CAMBRIDGE, England, Feb. 12, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2020. The full report can be accessed by clicking here.
Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: Sosei Heptares made a great deal of progress across all areas of its business in 2020, despite the challenges we faced. We adapted extremely well to the COVID-19 pandemic. This allowed us to successfully execute our strategy, adding several major partnering agreements around our early-stage programs, reinforcing our position as a leading go-to drug discovery and development partner. We also entered several strategic technology collaborations with innovative companie